Article Text

Gonorrhoea treatment position statement
  1. Helen Fifer1,
  2. Gwenda Hughes2,
  3. Keith Radcliffe3
  1. 1Sexually Transmitted Bacteria Reference Unit, Public Health England, London, UK
  2. 2HIV and STI Surveillance, PHE, London, UK
  3. 3Department of GU Medicine, Whittall Street Clinic, Birmingham, UK
  1. Correspondence to Dr Helen Fifer, Sexually Transmitted Bacteria Reference Unit, Public Health England, London NW9 5EQ, UK; helen.fifer{at}

Statistics from

The British Association of Sexual Health and HIV (BASHH) and Public Health England work in partnership to support clinicians with up-to-date guidance on managing sexually transmitted infections.

In 2011, the BASHH gonorrhoea treatment guidelines were changed to ceftriaxone 500 mg intramuscular in combination with azithromycin 1 g per oral, as first-line therapy. This dual therapy aims to delay the accumulation of resistance and extend the useful life of ceftriaxone.1 The advice has been widely adopted. Data from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) show that the regimen was used in 86% of patients in 2013. Most of the remainder received ceftriaxone plus doxycycline. Of this latter group, 65% were men who have sex with men and 29% were women; 36% had concurrent chlamydia, and 51% had rectal gonorrhoea. We have identified two main clinical scenarios where doxycycline …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.